Vimarsana
Biggest News Aggregation in the World

Week Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Week Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Week Study Today - Breaking & Trending Today

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity - Vimarsana News

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

Study Achieves Primary and all Secondary Endpoints, Demonstrating Statistically Significant Reductions in Body Weight at all Doses as Compared to Placebo Up to 13.1% Placebo-Adjusted Mean Weight...

Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity - Vimarsana News

Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

13-Week Study to Evaluate the Safety and Efficacy of VK2735 Dosed Weekly Trial Size Increased from 125 to 176 Patients Due to Elevated Demand SAN DIEGO, Oct. 23, 2023 /PRNewswire/ -- Viking...

Tenapanor Receives FDA Approval for Reducing Serum Phosphorous in CKD - Vimarsana News

Tenapanor Receives FDA Approval for Reducing Serum Phosphorous in CKD

On October 17, 2023, Ardelyx Inc announced the FDA approval of tenapanor (Xphozah) for reducing serum phosphorus in adults with chronic kidney disease on dialysis as add-on therapy.

Best Collagen Supplements Of 2023 - Vimarsana News

Best Collagen Supplements Of 2023

Whether you’re looking to improve joint pain, add a boost of hydration to your skin or support stronger hair and nails, a collagen supplement may be worth exploring. With the wide range of collagen supplements on the market, which is right for you? Narrow down your search with our top picks of .

Source: forbes.com
Viking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity - Vimarsana News

Viking Therapeutics Announces Initiation of Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity

/PRNewswire/ -- Viking Therapeutics, Inc. (Viking) (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for...